AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 62 min read$GRAL

Partridge Andrew John sold $91K of GRAL

Partridge Andrew John (Chief Growth Officer) sold 1,491 shares of GRAIL, Inc. (GRAL) at $61.08 on 2026-06-04.

Original reporting
SEC EDGAR · Partridge Andrew John
Published Jun 6, 2026, 12:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GRAL
Neutral
medium confidence
Mentioned
$GRAL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALNeutralLow
01

Why it matters

This adds a new datapoint on insider behavior but does not introduce new operational or financial information about GRAIL.

02

Market read

Traders may briefly reassess sentiment around GRAL due to insider selling, but the filing alone is unlikely to change valuation materially.

03

What to watch

The article doesn’t state whether other insiders bought/sold, whether there were concurrent grants, or the broader insider trading pattern; one sale is not a trend.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5; sale occurred June 4.

Background

The article is an SEC Form 4 insider transaction disclosure for GRAIL, Inc. (GRAL).

Company-level read

Ticker impact

$GRALNeutralMedium confidence
Context

GRAIL insider Chief Growth Officer Partridge sold 1,491 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing provides a single sale datapoint without new company fundamentals (no guidance, trial, or deal). The absence of a 10b5-1 plan can increase interpretive noise, but the dollar amount (~$91k) is typically not material versus market cap.

Market effects

Sector

Minimal—this is company-specific insider activity with no stated sector-wide change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may reflect diversification, liquidity needs, or tax planning rather than a bearish view, especially since insider transactions are often routine.

Key entities

  • issuer
    GRAIL, Inc.

    Public company whose insider transaction was reported on SEC Form 4.

  • insider
    Andrew John Partridge

    Chief Growth Officer who sold 1,491 shares on June 4 (reported via Form 4).

Read at source← All news

Related articles

AUG 8
$GRALMed

GRAIL Announces FDA Advisory Committee Review Of Galleri Multi-Cancer Early Detection Test

GRAIL said the FDA Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for Galleri, a multi-cancer early detection blood test. The submission cites PATHFINDER 2 (25,490 participants, one year) and NHS-Galleri (over 70,000). GRAIL says Galleri detects methylation patterns, with low false positives and accurate signal origin prediction.

rttnews.com2 min
AUG 5
$GRALMed

GRAIL, Inc. (GRAL): Results of Operations and Financial Condition

GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9912026q2earningspressre.htm EX-99.1 Document NEWS RELEASE Exhibit 99.1 GRAIL Reports Second Quarter 2026 Financial Results Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and

SEC EDGAR 8-K6 min
JUL 7
$GRALMed

GRAL Investment Deadline: GRAIL, Inc. Securities Fraud Class Action Focuses on Trial Results; Investors Notified of August 4 Court Deadline

Bleichmar Fonti & Auld LLP says a securities fraud class action was filed against GRAIL, Inc. (NASDAQ:GRAL) and executives after the company’s NHS-Galleri trial allegedly failed to support prior statements. The suit cites a ~50.55% stock drop (Feb. 19–20, 2026) and alleges violations of Exchange Act Sections 10(b) and 20(a). Investors have until Aug. 4, 2026 to seek lead-plaintiff status.

prnewswire.com2 min
JUN 4
$GRALLowAI 8/10

Is Grail Stock a Bad-News Buy After Its Recent Pullback?

Grail (NASDAQ: GRAL) shares fell after its February NHS England Galleri trial failed to meet the primary endpoint, though it reported fewer Stage IV cancers and some earlier detections. Galleri is not FDA-approved; it’s sold cash-only at $749–$949. Revenue rose from $93M (2023) to $147M (2025) while net loss narrowed. Full-year revenue is forecast to rise 22%–32%.

finance.yahoo.com6 min
JUN 1
$GRALMedAI 9/10

Why Grail Shares Crashed Today

Grail’s (GRAL) shares fell about 16% by midday after investors digested the company’s ASCO presentation on its Galleri multi-cancer early detection test with England’s NHS. The trial missed its primary endpoint for reducing later-stage cancers, though management cited clinically meaningful Stage IV reductions. Data showed 69.8% episode sensitivity for 12 key cancers but 39.3% for all cancers.

fool.com6 min
JUN 1
$GRALMedAI 9/10

GRAIL’s Galleri Test Cuts Stage 4 Cancer Diagnoses in Study Despite Missed Endpoint

GRAIL (NASDAQ:GRAL) reported new Galleri multi-cancer blood test data at ASCO, including NHS-Galleri and PATHFINDER 2 results. In NHS-Galleri (142,000+ participants), the primary endpoint—reducing combined stage 3/4 incidence after three rounds—was not met, but stage 4 fell >20% in incident rounds. Galleri increased screen-detected cancers ~4x; PATHFINDER 2 (36,000+) showed PPV 60.3%, specificity 99.6%, and mostly non-invasive diagnostics.

dailypolitical.com6 min